Business Context and Reporting Period
This Form 8-K Current Report was filed by Proteon Therapeutics, Inc. (PRTO) on May 10, 2019. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Waltham, MA. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the status of the Company's stock listing and does not contain financial performance data for the period.
Material Changes
The material change reported is the failure of the Company's common stock to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days (March 28, 2019, to May 9, 2019). Consequently, the Company no longer meets Nasdaq Listing Rule 5450(a)(1). This notice has no immediate effect on the trading of the stock, which continues on the Nasdaq Global Market.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 calendar days, until November 6, 2019, to regain compliance.
- Compliance Options: The Company may regain compliance if the bid price closes at $1.00 or more for 10 consecutive business days before the deadline. Alternatively, the Company may implement a reverse stock split, which must be completed no later than ten business days prior to November 6, 2019.
- Delisting Risk: If compliance is not achieved by the deadline and no additional period is granted, Nasdaq will initiate delisting proceedings. The Company retains the right to appeal such a determination to a Nasdaq Listing Qualifications Panel.
- Management Action: Management is monitoring the stock price and considering available options to achieve compliance.
Investor Verification Checklist
- Verify the current closing bid price of PRTO stock to assess the likelihood of regaining compliance via price recovery.
- Monitor Company announcements for any declaration of a reverse stock split before the October 2019 deadline.
- Review the Company's cash position in other filings (e.g., 10-Q or 10-K) to determine if liquidity constraints impact the ability to execute a reverse split or sustain operations during the compliance period.
- Confirm the exact deadline for the compliance period (November 6, 2019) and the specific requirements for the 10-day price recovery window.